Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/19869
Title: Heart rate reduction and exercise performance in recent onset heart failure with reduced ejection fraction: arguments for beta-blocker hypo-response
Authors: VERBRUGGE, Frederik 
Vrijsen, Jeroen
Vercammen, Jan
GRIETEN, Lars 
DUPONT, Matthias 
MULLENS, Wilfried 
Issue Date: 2015
Publisher: ACTA CARDIOLOGICA
Source: ACTA CARDIOLOGICA, 70 (5), p. 565-572
Abstract: Objective Beta blockers reduce all-cause mortality and readmissions in heart failure with reduced ejection fraction (HFrEF), which may be explained by their effect on heart rate (HR). This study assessed the impact of HR reduction with beta blockers on exercise capacity in recent onset HFrEF. Methods and results Fifty consecutive patients with recent onset HFrEF (<30 days) performed a standardized exercise protocol with respiratory gas analysis at baseline as well as after 6 and 12 months. Patients participated in a quality of care programme aiming to achieve guideline-recommended target doses for beta-blocker therapy. At baseline, 6 and 12 months, 36%, 70% and 62% of patients, respectively, had a resting HR <70 bpm. Beta-blocker dose after 12 months was comparable in patients with resting HR < 70 versus >= 70 bpm (P value = 0.631). However, with similar dose uptitration, the former versus the latter had a significantly larger HR reduction (17 +/- 22 versus 4 +/- 15 bpm; P value = 0.027). Peak oxygen consumption (VO2max) was significantly higher when resting HR was <70 versus 70 bpm (17.5 +/- 5.5 versus 14.4 +/- 3.3 mL/min/kg, respectively; P value = 0.038). Similar results were observed after 6 months. Patients in whom resting HR decreased at follow-up compared to baseline had a 2.0 +/- 3.2 mL/min/kg increase in VO2max compared to a 1.2 +/- 7.7 mL/min/kg increase in patients who did not demonstrate a lower resting HR (P value = 0.033). Conclusions In recent onset HFrEF, exercise performance was better when resting HR was controlled <70 bpm with beta-blocker therapy. However, despite aggressive dose uptitration, many patients did not achieve this target as they had little HR reduction with beta-blocker therapy.
Notes: [Verbrugge, Frederik H.; Vrijsen, Jeroen; Vercammen, Jan; Grieten, Lars; Dupont, Matthias; Mullens, Wilfried] Ziekenhuis Oost Limburg, Dept Cardiol, B-3600 Genk, Belgium. [Verbrugge, Frederik H.] Hasselt Univ, Doctoral Sch Med & Life Sci, Diepenbeek, Belgium. [Grieten, Lars; Mullens, Wilfried] Hasselt Univ, Fac Med & Life Sci, Biomed Res Inst, Diepenbeek, Belgium.
Keywords: Adrenergic beta antagonists; exercise tolerance; heart rate; systolic heart failure
Document URI: http://hdl.handle.net/1942/19869
ISSN: 0001-5385
e-ISSN: 1784-973X
DOI: 10.2143/AC.70.5.3110517
ISI #: 000364106000009
Category: A1
Type: Journal Contribution
Validations: ecoom 2016
Appears in Collections:Research publications

Files in This Item:
File Description SizeFormat 
Peeters (1).pdf1.13 MBAdobe PDFView/Open
Show full item record

SCOPUSTM   
Citations

2
checked on Sep 2, 2020

WEB OF SCIENCETM
Citations

3
checked on Apr 22, 2024

Page view(s)

50
checked on Jul 22, 2022

Download(s)

182
checked on Jul 22, 2022

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.